EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY 4.0

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19

Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo und 17 weitere

Journal of the Pediatric Infectious Diseases Society · 2024

DOI: 10.1093/jpids/piae105 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2024. Verfasst von Thomas D Norton und 28 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentSARS-CoV-2HumansChildMaleAdolescentFemaleChild, PreschoolAntiviral AgentsCOVID-19Drug CombinationsOutpatientsAntibodies, MonoclonalAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19monoclonal antibodiesoutpatientspediatricstreatment

Substanzen

Antibodies, Monoclonal, Humanizedcasirivimab and imdevimab drug combinationAntiviral AgentsDrug CombinationscasirivimabAntibodies, MonoclonalAntibodies, Neutralizing

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • Bio-Medical Research, Miami, Florida, USA.
  • Arizona Liver Health, Tucson, Arizona, USA.
  • Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.

ORCID-Profile: Eleftherios Mylonakis

Zitieren

APA

Norton, T. D., Thakur, M., Ganguly, S., Ali, S., Chao, J., Waldron, A., Xiao, J., Turner, K. C., Davis, J. D., Irvin, S. C., Pan, C., Atmodjo, D., Hooper, A. T., Hamilton, J. D., Hussein, M., Subramaniam, D., Roque-Guerrero, L., Kohli, A., Mylonakis, E., …, & Trial Investigators (2024). Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piae105

Vancouver

Norton TD, Thakur M, Ganguly S, Ali S, Chao J, Waldron A, et al. Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19. Journal of the Pediatric Infectious Diseases Society. 2024. doi:10.1093/jpids/piae105

BibTeX
@article{Norton2024,
  author = {Norton, Thomas D and Thakur, Mazhar and Ganguly, Samit and Ali, Shazia and Chao, Jesse and Waldron, Alpana and Xiao, Jing and Turner, Kenneth C and Davis, John D and Irvin, Susan C and Pan, Cynthia and Atmodjo, Dominique and Hooper, Andrea T and Hamilton, Jennifer D and Hussein, Mohamed and Subramaniam, Danise and Roque-Guerrero, Lilia and Kohli, Anita and Mylonakis, Eleftherios and Geba, Gregory P and Cox, Edward and Braunstein, Ned and Dakin, Paula and Kowal, Bari and Bhore, Rafia and DiCioccio, A Thomas and Hughes, Diana and Herman, Gary A and Trial Investigators, Trial Investigators},
  title = {Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2024},
  doi = {10.1093/jpids/piae105}
}
Kostenlos starten →